A study at the Center for Health Policy at IUPUI found that 66 cents of every dollar the state spends on services related to substance abuse goes toward health care while only 1 cent goes toward prevention or intervention.
The Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions, which could mean another $500 million in annual sales for Lilly, an analyst estimates.
Businessman J.B. Carlson is in debt for $5.9 million, and he may have been the last person to see 74-year-old Suzy Tomlinson alive. Her $15 million life-insurance policy named him as the beneficiary.
In Utah, employers can give each of their workers a specific amount of money to apply toward health insurance. The worker then can use that money to choose from the 66 plans in the health insurance exchange.
The federal legislation is roundly criticized at a BioCrossroads meeting, but some firms have found a silver lining.
The Indianapolis-based health insurer raised its full-year profit forecast by 20 cents per share, after lower-than-expected claims and lower administrative costs increased third-quarter profit by 1 percent.
Jim Hamilton, an employee-benefits lawyer at Bose McKinney & Evans in Indianapolis, discussed the likelihood of a Republican-controlled U.S. House of Representatives changing or even outright repealing the health care reform law, formally known as the Patient Protection and Affordable Care Act.
Excluding investment and special charges, the Carmel-based life and health insurer on Tuesday reported a profit $47.1 million, down 13 percent from the same quarter a year ago, but still beat analysts’ expectations.
After recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open a diabetes research center in China in the second half of 2011, further ramping up the drugmaker’s presence in the world’s fastest-growing pharmaceutical market.
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
St. Louis-based Ascension Health announced Friday morning that it would open a professional service center in Indianapolis, creating up to 500 jobs by 2013.
Carmel-based insurance lender Oak Street Funding LLC announced Thursday that it has been purchased by private equity funds managed by New York-based Angelo Gordon & Co.
Venture funds nationwide crested at $100 billion in 2000, but that number last year had drooped to $18 billion.
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
An Indiana couple is making a $45 million donation to the University of Maryland School of Medicine, which will use the money to establish a research center to study autoimmune and inflammatory diseases.
Warsaw-based Orthopedic implant maker Zimmer Holdings Inc. reported net income of $191.1 million, or 96 cents per share. Sales fell 1 percent to $965 million from $975.6 million.
Indianapolis-based Dow AgroSciences improved revenue during the third quarter thanks to a 26-percent increase in volume, but it still recorded a loss for the period.
Mark Long was president of the Indiana University Research & Technology Corp., which was responsible for the university’s tech transfer, before launching a consulting firm, Long Performance Advisors, in 2008.
Indiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched a website that aims to keep that talent in the state.
